Highline Capital Management’s AbbVie ABBV Stock Holding History

Highline Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,258,900	Closed	-$123M	–	27
2015 Q3	$123M	Buy	2,258,900 +32,900	+1%	+$2.14M	5.53%	6
2015 Q2	$150M	Buy	2,226,000 +37,700	+2%	+$2.46M	5.23%	1
2015 Q1	$128M	Sell	2,188,300 -258,000	-11%	-$15.6M	5.82%	2
2014 Q4	$160M	Buy	2,446,300 +92,600	+4%	+$5.84M	6.65%	1
2014 Q3	$136M	Buy	2,353,700 +91,900	+4%	+$5.1M	5.3%	3
2014 Q2	$128M	Buy	2,261,800 +192,500	+9%	+$10.1M	6.48%	1
2014 Q1	$106M	Buy	2,069,300 +2,035,500	+6,022%	+$103M	7.3%	2
2013 Q4	$1.78M	Buy	+33,800	New	+$1.66M	0.11%	26
2013 Q3	–	Sell	-938,200	Closed	-$41.6M	–	30
2013 Q2	$38.8M	Buy	+938,200	New	+$41M	3.16%	16

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Highline Capital Management's ABBV Position: Q4 2015 in Review

Highline Capital Management sold out of AbbVie (ABBV) in Q4 2015, closing a stake of 2,258,900 shares — an estimated $123M sold.

Highline Capital Management first reported a position in ABBV in Q2 2013 and held it in 9 quarters. The position peaked at $160M in Q4 2014. 1,635 funds tracked by Wall St. Rank hold ABBV as of Q4 2015.

Highline Capital Management reported no remaining AbbVie position as of Q4 2015 after selling out during the quarter.
Highline Capital Management sold 2,258,900 AbbVie shares in Q4 2015, an estimated $123M.
Highline Capital Management first reported a position in AbbVie in Q2 2013 and held it in 9 quarters.
Highline Capital Management's AbbVie position peaked at $160M in Q4 2014.
1,635 funds tracked by Wall St. Rank held AbbVie as of Q4 2015.

Based on Highline Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.